vivoVerse

Executive Summary

vivoVerse is a San Francisco-based biotechnology company pioneering a transformative approach to toxicology testing. Traditional developmental and reproductive toxicity (DART) assays rely on costly, time-consuming mammalian studies, often taking years and involving significant animal use. vivoVerse’s platform, vivoScreen, leverages the C. elegans nematode model integrated with proprietary microfluidics and AI-driven image analysis to enable high-throughput, automated whole-organism screening. The flagship vivoDART™ assay delivers rapid, cost-effective DART data, potentially reducing assay timelines from months to weeks while improving human relevance. This innovation aligns with regulatory shifts like the FDA Modernization Act 2.0, which encourages alternative methods to animal testing. vivoVerse targets the $5B+ preclinical toxicology market, offering a scalable solution that pharma and chemical companies urgently need to accelerate drug development and reduce costs. The company is pre-revenue but has demonstrated platform feasibility through early validation studies. Key upcoming catalysts include securing a strategic partnership with a top-20 pharmaceutical company for assay deployment, achieving formal qualification of vivoDART™ with a major regulatory agency, and closing a Series A funding round to scale operations. With strong scientific foundations and growing regulatory tailwinds, vivoVerse is positioned to disrupt the toxicology testing landscape.

Upcoming Catalysts (preview)

• Q3 2026Strategic Partnership with Top-20 Pharma60% success
• Q4 2026FDA Qualification of vivoDART™ Assay30% success
• Q2 2026Series A Funding Round Closure70% success